Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo (pegfilgrastim)
- Biosimilar Ziextenzo(pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1]
- Ziextenzo is indicated to reduce duration of neutropenia / incidence of febrile neutropenia, some of the most serious side effects of chemotherapy [2]
- Sandoz demonstrates commitment to making access happen for patients with eight biosimilars approved in EU, including five in last 18 months